Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03040141 · ClinicalTrials.gov registry record · Phase 2
Study of Efficacy and Safety of IV VIS410 Plus Oseltamivir Versus Oseltamivir in Hospitalized Adults With Influenza A
A Phase 2 study of Influenza a, sponsored by Visterra.
- Completed
- Registry status
- Phase 2
- Development phase
- 89
- Enrollment target
- 20
- Study locations
NCT03040141: Completed Phase 2 study of Influenza a, sponsored by Visterra.
NCT03040141 is a Phase 2 study of Influenza a that has completed, run by Visterra. The registered enrollment target is 89 participants, below the 2,745-participant average among 10 other Influenza a trials with a reported enrollment target (97% lower). The trial reports 20 study locations across 14 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03040141, a Phase 2 study of Influenza a, has completed, sponsored by Visterra.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 89 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study is to compare the efficacy and safety of VIS410 in combination with oseltamivir vs oseltamivir alone in severely ill subjects with influenza A infection requiring oxygen support.
Primary Outcome
Evaluate the effect of 2 dose levels of VIS410 + oseltamivir on clinical status using a seven-level ordinal scale. Comparison between treatment groups and between all VIS410 recipients versus placebo were assessed.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Low dose of VIS410
- DRUG High dose of VIS410
Study Locations (20)
Pennsylvania
- Visterra - Allentown
- Visterra - Philadelphia
- Visterra - York
Georgia
- Visterra - Atlanta
- Visterra - Decatur
New York
- Visterra - Albany
- Visterra - Syracuse
North Carolina
- Visterra - Durham
- Visterra - Greensboro
Ohio
- Visterra - Cleveland
- Visterra - Columbus
Arizona
- Visterra - Tucson
California
- Visterra - Stanford
Florida
- Visterra - St. Petersburg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 89 participants |
| Start Date | 2018-01-03 |
| Est. Completion | 2018-11-22 |
| Phase | Phase 2 |
What the finished NCT03040141 record still lists
NCT03040141 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 89 participants, a relatively small participant target, below the 2,745-participant average among 10 other Influenza a trials with a reported enrollment target (97% lower).
The record links to 1 condition, with Influenza a appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT03040141 names 20 study sites across 14 states, led by Pennsylvania, Georgia, New York.
Frequently Asked Questions
What is clinical trial NCT03040141 about?
NCT03040141 is a clinical study titled "Study of Efficacy and Safety of IV VIS410 Plus Oseltamivir Versus Oseltamivir in Hospitalized Adults With Influenza A". This study is to compare the efficacy and safety of VIS410 in combination with oseltamivir vs oseltamivir alone in severely ill subjects with influenza A infection requiring oxygen support.
What is the current status of trial NCT03040141?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 89 participants. The study started on 2018-01-03. Estimated completion is 2018-11-22.
What conditions does trial NCT03040141 study?
This clinical trial studies the following conditions: Influenza a.
What interventions are being tested in trial NCT03040141?
The interventions under investigation include: Placebo (DRUG), Low dose of VIS410 (DRUG), High dose of VIS410 (DRUG).
Who is sponsoring clinical trial NCT03040141?
This trial is sponsored by Visterra, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03040141 being conducted?
This trial has 20 study locations across Arizona, California, Florida, Georgia, Idaho. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Influenza a
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03040141's enrollment target sits among peer trials
89 9th of 10 higher than 2 of 10 other Influenza a trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Influenza a trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Multi-Site Clinical Evaluation of the LIAISON NES FLU A/B, RSV & COVID-19 Assay in Symptomatic Patients
RECRUITING · NA
-
A Phase I/II Study on Safety AND Immunogenicity of AZD4117 and AZD5315 Vaccines (PANDA)
ACTIVE NOT RECRUITING · Phase 1
-
Safety and Immunogenicity of the Bris10 M2SR and Sing2016 M2SR H3N2 Monovalent Influenza Vaccines
COMPLETED · Phase 1
-
Wearable Assisted Viral Evidence (WAVE) Study A Decentralized, Prospective Study Exploring the Relationship Between Passively-collected Data From Wearable Activity Devices and Respiratory Viral Infections
COMPLETED
-
Evaluating the Safety and Efficacy of Anti-Influenza Intravenous Hyperimmune Immunoglobulin (IVIG) in Adults Hospitalized With Influenza
COMPLETED · Phase 3
-
Safety and Immunogenicity of Live Influenza A Vaccine for Avian Influenza H7N7
COMPLETED · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03682289 · 89 participants · Phase 2
Ceralasertib (AZD6738) Alone and in Combination With Olaparib or Durvalumab in Patients With Solid Tumors
- NCT04787939 · 89 participants · NA
Early Feeding After Oral Cavity Reconstruction
- NCT05480449 · 89 participants · Phase 1
Autologous HuCART19 T Cells Manufactured Using the CliniMACS Prodigy Platform for Pediatric B-ALL (huCART19 Prodigy)
- NCT05604131 · 89 participants · Phase 2
Cardiac MRI-guided Deferiprone Therapy for Acute Myocardial Infarction Patients
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI